A Targeted Alpha-Particle Radiopharmaceutical for Bone Metastatic Breast Cancer
Abstract
The proposed studies will develop and evaluate a new therapeutic strategy for treating breast cancer bone metastasis by disrupting the interactions between breast cancer cells and sensory neurons within bone using alpha particle-emitting radiopharmaceuticals that target the CGRP-CRLR axis. The successful completion of this project will establish a new therapeutic target for cancer-induced bone pain and bone metastatic breast cancer; while providing the foundation required to develop new therapies that will decrease suffering and improve survival of breast cancer patients with bone metastases. During this period, we encountered COVID-19-related issues which have negatively impacted our productivity. However, after conducting online training with Dr. Wadas, Dr. Shiozawa obtained institutional radiation safety approval to perform proposed work in November 2021 so that Dr. Shiozawa is able to perform radioactive work at Wake Forest School of Medicine. Additionally, we have created the CRLC-over-expressing breast cancer cells which will be used to evaluate the 225Ac-PTCA-CGRP27-37 peptides in vitro and in vivo during the next year. The team also completed the first radiochemistry experiments with the PCTA-CGRP27-37 peptides and developed strategies to overcome the severe lipophilicity of the agents under investigation.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1177558
Entities
People
- Thaddeus J Wadas
- Yusuke Shiozawa
Organizations
- University of Iowa
- Wake Forest University